CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for QUIA PHARMA AB (publ) is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

QUIA PHARMA AB (publ)
Uppsala Business Park
Virdings Alle 32 B
Phone: +46 87780006p:+46 87780006 UPPSALA, 754 50  Sweden Ticker: QUIAQUIA
Business Summary
QUIA PHARMA AB (publ) is a pharmaceutical development company based on a patented drug delivery based on a platform technology, Uni-Qleaver, which helps to release an active pharmaceutical ingredient in a controlled manner over time. The Company develops improved and patentable forms of drugs under development or already approved by drug authorities. These forms of drugs are based on the Company's technology platform. In addition, the Company offers global sales of omega-3, astaxin and collagen through Amazon. The Company's technology platform can be used for the development of drug substances that have promising biological effects but challenging pharmacological properties as well as improved versions of already approved drugs called biobetters.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202412/31/2023Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research
5122 Drugs, drug proprietaries, and druggists' sundries

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board Per S.Thoresen 69 1/1/2022 1/1/2021
Chief Executive Officer, Director MarcusBosson 3/29/2017 3/29/2017
Chief Financial Officer HjordisBerg 67 6/3/2022 6/3/2022
6 additional Officers and Directors records available in full report.

Business Names
Business Name
LUCE
Lucent Oil AB
QUIA
Viatech Systems AB

General Information
Number of Employees: 8 (As of 6/30/2013)
Outstanding Shares: 3,366,573,200 (As of 2/18/2025)
Shareholders: 462
Stock Exchange: STO
Fax Number: +46 87780005


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, April 19, 2025